Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications
News provided by
Share this article
Share this article
LOS ANGELES, May 11, 2021 /PRNewswire/ Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealth backed by $52 million Series A financing led by 8VC. Other investors included Two Sigma Ventures, among others, and participation from seed investors Sherpa Healthcare Partners and Freeflow Ventures.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Dive Brief:
Ginkgo Bioworks, a specialist in engineering cells for biotechnology, industrial and agricultural uses, will go public by merging with a special purpose acquisition company, or SPAC, in a deal that values the company at a lofty $15 billion.
The merger with Soaring Eagle Acquisition Corp. will give Ginkgo Bioworks a place on the Nasdaq stock exchange as well as approximately $2.5 billion in proceeds, $775 million of which will come through private investments in public equity by an array of high-profile backers.
Eagle Equity Partners is co-sponsoring the deal with Bellco Capital, an investment firm led by Arie Belldegrun, the founder of cancer cell therapy companies Kite Pharma and Allogene Therapeutics. Both Eagle and Bellco are investing in Ginkgo stock at $10 per share.
Operator
Good day everyone, and welcome to today s ANI Pharmaceuticals First Quarter 2021 Earnings Release Call. [Operator Instructions]
It s now my pleasure to turn the conference over to Lisa Wilson. Please go ahead.
Lisa M. Wilson
Investor Relations
Thank you, operator. Welcome to ANI Pharmaceuticals Q1 2021 earnings results call. This is Lisa Wilson of In-Site Communications, Investor Relations for ANI. With me on today s call are Nikhil Lalwani, President and Chief Executive Officer; and Stephen Carey, Chief Financial Officer of ANI. You can also access the webcast of this call through the Investors section of the ANI website at anipharmaceuticals.com.